(AMPH) Amphastar P - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US03209R1032

AMPH: Injectables, Inhalation, Nasal, Sprays, Vaccines, Medicines

Amphastar Pharmaceuticals (NASDAQ:AMPH) is a bio-pharmaceutical company with a focus on injectable, inhalation, and intranasal products. Operating primarily in the U.S., China, and France, they offer a mix of generic and proprietary drugs. Their product portfolio includes BAQSIMI, a nasal spray for severe hypoglycemia, and Primatene Mist, an OTC epinephrine inhaler for mild asthma. Enoxaparin, used to prevent deep vein thrombosis, is another key product, alongside Rextovy and Naloxone for opioid overdose treatment. They also provide Glucagon emergency kits and Cortrosyn for diagnostic purposes.

The companys range extends to anesthetic and emergency products such as Amphadase, Epinephrine injections, and Lidocaine jelly. They distribute insulin APIs, a significant part of their business. Amphastar is actively developing generics, biosimilars, and an intranasal epinephrine spray, showcasing their commitment to innovation and pipeline growth.

Financially, Amphastar has a market cap of around $1.5 billion, with a P/E ratio of 10.55, indicating a reasonable valuation. Their P/B ratio of 2.10 and P/S of 2.06 are key metrics for investors assessing the companys financial health and market position.

Additional Sources for AMPH Stock

AMPH Stock Overview

Market Cap in USD 1,349m
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
GiC Sub-Industry Pharmaceuticals
IPO / Inception 2014-06-25

AMPH Stock Ratings

Growth 5y 48.2%
Fundamental 79.1%
Dividend 0.0%
Rel. Strength Industry -39.6
Analysts 4/5
Fair Price Momentum 23.45 USD
Fair Price DCF 83.58 USD

AMPH Dividends

No Dividends Paid

AMPH Growth Ratios

Growth Correlation 3m -94.9%
Growth Correlation 12m -25.5%
Growth Correlation 5y 83.9%
CAGR 5y 15.02%
CAGR/Max DD 5y 0.25
Sharpe Ratio 12m -1.33
Alpha -46.65
Beta 0.67
Volatility 46.64%
Current Volume 467.6k
Average Volume 20d 562.9k
What is the price of AMPH stocks?
As of March 14, 2025, the stock is trading at USD 26.24 with a total of 467,567 shares traded.
Over the past week, the price has changed by -7.34%, over one month by -17.33%, over three months by -37.88% and over the past year by -39.75%.
Is Amphastar P a good stock to buy?
Yes, based on ValueRay Fundamental Analyses, Amphastar P (NASDAQ:AMPH) is currently (March 2025) a good stock to buy. It has a ValueRay Fundamental Rating of 79.08 and therefor a positive outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of AMPH as of March 2025 is 23.45. This means that AMPH is currently overvalued and has a potential downside of -10.63%.
Is AMPH a buy, sell or hold?
Amphastar P has received a consensus analysts rating of 4.00. Therefor, it is recommend to buy AMPH.
  • Strong Buy: 2
  • Buy: 2
  • Hold: 2
  • Sell: 0
  • Strong Sell: 0
What are the forecast for AMPH stock price target?
According to ValueRays Forecast Model, AMPH Amphastar P will be worth about 25.5 in March 2026. The stock is currently trading at 26.24. This means that the stock has a potential downside of -2.74%.
Issuer Forecast Upside
Wallstreet Target Price 39.8 51.7%
Analysts Target Price 56.4 114.9%
ValueRay Target Price 25.5 -2.7%